Open AccessEvaluating the utility of intralipid infusion to improve live birth rates in patients with recurrent pregnancy loss or recurrent implantation failure
Author(s) -
Anne E. Martini,
S. Jasulaitis,
Louis Fogg,
Meike L. Uhler,
Jennifer HirshfeldCytron
Publication year - 2018
Publication title -
journal of human reproductive sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.484
H-Index - 31
eISSN - 0974-1208
pISSN - 1998-4766
DOI - 10.4103/jhrs.jhrs_28_18
Subject(s) - live birth , medicine , pregnancy , population , obstetrics , demographics , gestational age , demography , biology , genetics , environmental health , sociology
Intralipid is used to improve clinical outcomes in patients with recurrent pregnancy loss (RPL) or recurrent implantation failure (RIF) with elevated natural killer (NK) cells. Data supporting this practice is conflicting but suggestive of minimal benefit.